Non-Coding RNAs Regulate Spontaneous Abortion: A Global Network and System Perspective

Gan, Jianyu; Gu, Tao; Yang, Huaqiang; Ao, Zheng; Cai, Guangyan; Hong, Linjun; Wu, Zhenfang

doi:10.3390/ijms23084214

Cited by 11 publications

(8 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LncRNAs and circRNAs have been shown to exert their biological functions by acting as sponges or molecular sinks for miRNAs, RBPs, and transcription factors to specifically modulate their target gene expression. These ncRNAs are also called intracellular competitive endogenous RNAs (ceRNAs) ( 40 , 41 ). For instance, lncRNA SLC25A25-AS1 was found to promote proliferation, migration, and invasion, and induced apoptosis in NSCLC A549 and H460 cells by upregulating integrin α2 via sponging miR-195-5p ( 42 ).…”

Section: Overview Of Ncrnasmentioning

confidence: 99%

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Zhou

Jia

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Cancer is one of the most frequently diagnosed malignant diseases worldwide, posing a serious, long-term threat to patients’ health and life. Systemic chemotherapy remains the first-line therapeutic approach for recurrent or metastatic cancer patients after surgery, with the potential to effectively extend patient survival. However, the development of drug resistance seriously limits the clinical efficiency of chemotherapy and ultimately results in treatment failure and patient death. A large number of studies have shown that non-coding RNAs (ncRNAs), particularly microRNAs, long non-coding RNAs, and circular RNAs, are widely involved in the regulation of cancer drug resistance. Their dysregulation contributes to the development of cancer drug resistance by modulating the expression of specific target genes involved in cellular apoptosis, autophagy, drug efflux, epithelial-to-mesenchymal transition (EMT), and cancer stem cells (CSCs). Moreover, some ncRNAs also possess great potential as efficient, specific biomarkers in diagnosis and prognosis as well as therapeutic targets in cancer patients. In this review, we summarize the recent findings on the emerging role and underlying mechanisms of ncRNAs involved in cancer drug resistance and focus on their clinical applications as biomarkers and therapeutic targets in cancer treatment. This information will be of great benefit to early diagnosis and prognostic assessments of cancer as well as the development of ncRNA-based therapeutic strategies for cancer patients.

show abstract

Section: Overview Of Ncrnasmentioning

confidence: 99%

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Zhou

Jia

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Long non-coding RNAs (lncRNAs), defined as endogenous cellular RNAs with a length exceeding 200 nucleotides, 5 have been found to serve as important regulators for fine-tuning gene expression and cellular pathophysiological processes under different stimuli through competing endogenous RNA networks 6 , 7 and signaling pathways. 8 Moreover, some LncRNAs are involved in the control of gene imprinting and are imprinted, showing parent-of-origin allelic expression.…”

Section: Introductionmentioning

confidence: 99%

Hypomethylation of the LncRNA H19 promoter accelerates osteogenic differentiation of vascular smooth muscle cells by activating the Erk1/2 pathways

Wang,

Cheng,

Jin

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

Objective Vascular calcification is a common chronic kidney disease complication. This study aimed to investigate the function of long non-coding RNA (LncRNA) H19 in vascular calcification to explore new therapeutic strategies. Methods We induced osteogenic differentiation and calcification of vascular smooth muscle cells (VSMCs) using β-glycerophosphate. Then, we detected the LncRNA H19 promoter methylation status and Erk1/2 pathways using methylation-specific polymerase chain reaction and western blotting, respectively. Results Compared with the control group, high phosphorus levels induced VSMC calcification, accompanied by increases in LncRNA H19 and the osteogenic marker Runx2 and reduction of the contractile phenotype marker SM22a. LncRNA H19 knockdown inhibited osteogenic differentiation and calcification of VSMCs. However, the suppressed role of VSMC calcification caused by shRNA H19 was partially reversed by simultaneous activation of the Erk1/2 pathways. Mechanically, we found that the methylation rate of CpG islands in the LncRNA H19 promoter region was significantly lower in the high-phosphorus group, and the hypomethylation state elevated LncRNA H19 levels, which in turn regulated phosphorylated Erk1/2 expression. Conclusions LncRNA H19 promoted osteogenic differentiation and calcification of VSMCs by regulating the Erk1/2 pathways. Additionally, hypomethylation of LncRNA H19 promoter CpG islands upregulated LncRNA H19 levels and subsequently activated Erk1/2 phosphorylation.

show abstract

“…Many researchers have noticed that ceRNA interactions play important roles in several complicated diseases, encompassing immune-related diseases [ 38 ] and cardiovascular diseases [ 39 ]. Significantly, ceRNA also assumes a pivotal role in the domain of women’s reproductive health [ 40 ], including endometriosis [ 41 ], fetal and organ development [ 42 ], spontaneous abortion [ 43 ], intrahepatic cholestasis and eclampsia in pregnancy [ 44 , 45 ]. Previous studies have been conducted to construct competing ceRNA networks in PCOS.…”

Section: Introductionmentioning

confidence: 99%

Immune dysfunction mediated by the competitive endogenous RNA network in fetal side placental tissue of polycystic ovary syndrome

Xie,

Wang,

Chen

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS), a common endocrine and metabolic disorder affecting women in their reproductive years. Emerging evidence suggests that the maternal-fetal immune system is crucial for proper pregnancy. However, whether immune function is altered at the end of pregnancy in PCOS women and the underlying molecular mechanisms is currently unexplored. Herein, the basic maternal immune system was investigated (n = 136 in the control group; n = 103 in the PCOS group), and whole-transcriptome sequencing was carried out to quantify the mRNAs, miRNAs, and lncRNAs expression levels in fetal side placental tissue of women with PCOS. GO, KEGG, and GSEA analysis were employed for functional enrichment analysis. The process of identifying hub genes was conducted utilizing the protein-protein interaction network. CIBERSORT and Connectivity Map were deployed to determine immune cell infiltration and predict potential drugs, respectively. A network of mRNA-miRNA-lncRNA was constructed and then validated by qRT-PCR. First, red blood cell count, neutrophil count, lymphocyte count, hypersensitive C-reactive protein, and procalcitonin were significantly elevated, while placental growth factor was hindered in PCOS women. We identified 308 DEmRNAs, 77 DEmiRNAs, and 332 DElncRNAs in PCOS samples. Functional enrichment analysis revealed that there were significant changes observed in terms of the immune system, especially the chemokine pathway. Eight genes, including FOS, JUN, EGR1, CXCL10, CXCR1, CXCR2, CXCL11, and CXCL8, were considered as hub genes. Furthermore, the degree of infiltration of neutrophils was dramatically decreased in PCOS tissues. In total, 57 ceRNA events were finally obtained, and immune-related ceRNA networks were validated. Some potential drug candidates, such as enalapril and RS-100329, could have a function in PCOS therapy. This study represents the inaugural attempt to evaluate the immune system at the end of pregnancy and placental ceRNA networks in PCOS, indicating alterations in the chemokine pathway, which may impact fetal and placental growth, and provides new therapy targets.

show abstract

Non-Coding RNAs Regulate Spontaneous Abortion: A Global Network and System Perspective

Cited by 11 publications

References 129 publications

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications

Hypomethylation of the LncRNA H19 promoter accelerates osteogenic differentiation of vascular smooth muscle cells by activating the Erk1/2 pathways

Immune dysfunction mediated by the competitive endogenous RNA network in fetal side placental tissue of polycystic ovary syndrome

Contact Info

Product

Resources

About